Singapore, March 24 -- CHA Biotech and Novartis Korea have signed a strategic Memorandum of Understanding (MoU) to establish a collaborative framework for bio open innovation based on the Cell Gene Bioplatform (CGB).Through this agreement, both companies plan to establish a cooperative system to support the discovery of innovative technologies, commercialisation, and global expansion of promising bio startups. They will jointly implement initiatives with bio startups, including technology scouting programmes for discovering innovative technologies, mentoring and education programmes, and networking events.

Additionally, they will explore investment linkages, global partnership opportunities, and potential collaborations with the governme...